Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Email alerts

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Researcher index

Authors in the psilocybin and psilocin literature

Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.

Kochelski Esti

205 indexed publications match this author name.

ORCID
Not found in stored metadata
OpenAlex
Not found in stored metadata

Author watchlist

Create a confirmed email alert for new publications matching this author.

Publication history

Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's DiseaseClinicalTrials.gov · 2026-10-02Open-label, Single-arm fMRI Study Evaluating the Effects of Psilocybin on Craving in Nicotine Dependence.ClinicalTrials.gov · 2026-10-01PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin PretreatmentClinicalTrials.gov · 2026-10-01The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSDClinicalTrials.gov · 2026-10-01A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderClinicalTrials.gov · 2026-10-01Consciousness and Psilocybin Effects on Well-Being: The CoPEWell StudyClinicalTrials.gov · 2026-09-29The Efficacy of Psilocybin Therapy for Depression in Parkinson's DiseaseClinicalTrials.gov · 2026-09-28Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot StudyClinicalTrials.gov · 2026-09-24Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized TrialClinicalTrials.gov · 2026-09-24Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility StudyClinicalTrials.gov · 2026-09-23ADEPT: Augmenting DBT Effectiveness With Psilocybin-Assisted TherapyClinicalTrials.gov · 2026-09-22Psilocybin in the Treatment of Methamphetamine Use DisorderClinicalTrials.gov · 2026-09-21Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)ClinicalTrials.gov · 2026-09-21A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older AdultsClinicalTrials.gov · 2026-09-16Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled TrialClinicalTrials.gov · 2026-09-15PRoMiSS: Psilocybin and the Role of Music in Set and SettingClinicalTrials.gov · 2026-09-15Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual AnhedoniaClinicalTrials.gov · 2026-09-15Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled TrialClinicalTrials.gov · 2026-09-15A Phase 1b Study to Evaluate the Safety and Tolerability of MLS101 Treatment for Premenstrual Dysphoric Disorder (PMDD)ClinicalTrials.gov · 2026-09-14Pilot Study on the Effects of Psilocybin on Belief Updating and Insight FormationClinicalTrials.gov · 2026-09-14Psilocybin Administration With 5-HT1a BlockadeClinicalTrials.gov · 2026-09-14TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance TherapyClinicalTrials.gov · 2026-09-11A Randomized Double-blinded Controlled Trial for the Treatment of Persisting Symptoms After Concussion With Psilocybin-assisted Therapy: A Safety and Feasibility TrialClinicalTrials.gov · 2026-09-09A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's DiseaseClinicalTrials.gov · 2026-09-09Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner ViolenceClinicalTrials.gov · 2026-09-08Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's DiseaseClinicalTrials.gov · 2026-09-04Psilocybin and Affective Function in Chronic Lower Back Pain DepressionClinicalTrials.gov · 2026-09-04Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-09-04Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in RemissionClinicalTrials.gov · 2026-09-04High vs. Low-Dose Group-Based Psilocybin-Assisted Therapy (PAT) With or Without Mindfulness-Based (MB) Preparation and Integration for Demoralization in Adults With Advanced Cancer (PAT-MIND): A Pilot Feasibility 2x2 Factorial Multisite TrialClinicalTrials.gov · 2026-09-02Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use DisorderClinicalTrials.gov · 2026-09-02The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy AdultsClinicalTrials.gov · 2026-09-02Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]ClinicalTrials.gov · 2026-09-02NeuroGuard: Psilocybin Trial for Preventing Chemo-induced NeuropathyClinicalTrials.gov · 2026-08-31An 8-week Phase 2 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-assisted-psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept StudyClinicalTrials.gov · 2026-08-31Psilocybin-Assisted Psychotherapy for Posttraumatic Stress Disorder in Military Veterans: A Pilot Feasibility StudyClinicalTrials.gov · 2026-08-28Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical TrialClinicalTrials.gov · 2026-08-21Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy OutcomesClinicalTrials.gov · 2026-08-19An Exploratory Pilot Study of Palliadelic Treatment to Reduce Psychological Distress in People With Pancreatobiliary and Other Advanced Gastrointestinal CancersClinicalTrials.gov · 2026-08-19An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in LifeClinicalTrials.gov · 2026-08-17The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young AdultsClinicalTrials.gov · 2026-08-14A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in VeteransClinicalTrials.gov · 2026-08-14Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)ClinicalTrials.gov · 2026-08-13Processing Intergenerational Trauma With Psilocybin-Assisted TherapyClinicalTrials.gov · 2026-08-13The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive DisorderClinicalTrials.gov · 2026-08-13PsiloStudy: A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-08-13TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer SurvivorsClinicalTrials.gov · 2026-08-12Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and SuicidalityClinicalTrials.gov · 2026-08-12Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring OpioidsClinicalTrials.gov · 2026-08-12A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety DisorderClinicalTrials.gov · 2026-08-12Psilocybin Recovery Intervention for Stopping Methamphetamine UseClinicalTrials.gov · 2026-08-11Effects of Psilocybin in Patients With Amyotrophic Lateral SclerosisClinicalTrials.gov · 2026-08-11An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)ClinicalTrials.gov · 2026-08-10Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord InjuryClinicalTrials.gov · 2026-08-10Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot StudyClinicalTrials.gov · 2026-08-10The Efficacy of Psilocybin Therapy for Depression in Parkinson's DiseaseClinicalTrials.gov · 2026-08-07Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use DisorderClinicalTrials.gov · 2026-08-06Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand MechanismClinicalTrials.gov · 2026-08-06An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic TherapyClinicalTrials.gov · 2026-08-06Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced CancerClinicalTrials.gov · 2026-08-05Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic TherapiesClinicalTrials.gov · 2026-08-04Psilocybin as a Treatment for Chronic Pain in SmokersClinicalTrials.gov · 2026-08-03A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and DepressionClinicalTrials.gov · 2026-07-31Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant DepressionClinicalTrials.gov · 2026-07-30Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for Post-Traumatic Stress DisorderClinicalTrials.gov · 2026-07-30Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)ClinicalTrials.gov · 2026-07-30Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical TrialClinicalTrials.gov · 2026-07-30An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSDClinicalTrials.gov · 2026-07-29Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of PsilocybinClinicalTrials.gov · 2026-07-29Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.ClinicalTrials.gov · 2026-07-28A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.ClinicalTrials.gov · 2026-07-23Effects of Psilocybin on Electrophysiology and the Dynamic Content of ThoughtClinicalTrials.gov · 2026-07-23A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe AnxietyClinicalTrials.gov · 2026-07-23Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind TrialClinicalTrials.gov · 2026-07-17Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled TrialClinicalTrials.gov · 2026-07-14Mechanistic Studies of Psilocybin in Headache DisordersClinicalTrials.gov · 2026-07-13PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical TrialClinicalTrials.gov · 2026-07-10PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical TrialClinicalTrials.gov · 2026-07-10Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the BrainClinicalTrials.gov · 2026-07-10The Effects of Psilocybin on Social ConnectednessClinicalTrials.gov · 2026-07-09Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)ClinicalTrials.gov · 2026-07-09Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use DisorderClinicalTrials.gov · 2026-07-09Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone FormulationClinicalTrials.gov · 2026-07-07Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)ClinicalTrials.gov · 2026-07-07Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive SymptomsClinicalTrials.gov · 2026-07-01A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-07-015-HT2A Agonist Psilocybin in the Treatment of Tobacco Use DisorderClinicalTrials.gov · 2026-06-29Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label TrialClinicalTrials.gov · 2026-06-26A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-06-25Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label TrialClinicalTrials.gov · 2026-06-23Psilocybin-Assisted Therapy for Prolonged GriefClinicalTrials.gov · 2026-06-23Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and EfficacyClinicalTrials.gov · 2026-06-22Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label TrialClinicalTrials.gov · 2026-06-22The Acute Effects of Psilocybin on Cognition, Memory, and Brain FunctionClinicalTrials.gov · 2026-06-15Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-samplingClinicalTrials.gov · 2026-06-052 x 2 Factorial, Double-blind, Randomized Trial of 'Set and Setting': a Translational Study in Healthy VolunteersClinicalTrials.gov · 2026-06-04Group Psilocybin-Assisted Therapy for Post-Traumatic Stress DisorderClinicalTrials.gov · 2026-05-22A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for DepressionClinicalTrials.gov · 2026-05-20Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)ClinicalTrials.gov · 2026-05-14Psilocybin for Treatment of Obsessive Compulsive DisorderClinicalTrials.gov · 2026-05-12The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.ClinicalTrials.gov · 2026-05-08A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With CancerClinicalTrials.gov · 2026-05-06A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive DisorderClinicalTrials.gov · 2026-05-06A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of DepressionClinicalTrials.gov · 2026-05-04Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive DisorderClinicalTrials.gov · 2026-05-04Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)ClinicalTrials.gov · 2026-04-29A Double-blind, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People With Chronic Low Back PainClinicalTrials.gov · 2026-04-29Psilocybin-Enhanced Psychotherapy for Methamphetamine Use DisorderClinicalTrials.gov · 2026-04-22Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted PsychotherapyClinicalTrials.gov · 2026-04-22CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical TrialClinicalTrials.gov · 2026-04-13Safety Profile of 25 mg Psilocybin in Individuals With Cocaine Use DisorderClinicalTrials.gov · 2026-04-07Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in DepressionClinicalTrials.gov · 2026-03-30Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use DisorderClinicalTrials.gov · 2026-03-30Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory DepressionClinicalTrials.gov · 2026-03-27Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging TrialClinicalTrials.gov · 2026-03-24Pilot Study of Psilocybin-assisted Treatment for Cannabis Use DisorderClinicalTrials.gov · 2026-03-18Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot StudyClinicalTrials.gov · 2026-03-18Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use DisorderClinicalTrials.gov · 2026-03-13Psilocybin-facilitated Treatment for Chronic PainClinicalTrials.gov · 2026-03-11Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept StudyClinicalTrials.gov · 2026-03-11Pilot Proof of Concept Study Evaluating the Potential Psilocybin Assisted Psychotherapy (PAP) as a Therapeutic Tool for Patients Suffering From Severe Irritable Bowel Syndrome.ClinicalTrials.gov · 2026-03-05Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept TrialClinicalTrials.gov · 2026-03-04A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.ClinicalTrials.gov · 2026-03-03Study of Psilocybin for Anorexia in Young AdultsClinicalTrials.gov · 2026-03-03Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive ImpairmentClinicalTrials.gov · 2026-02-25The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.ClinicalTrials.gov · 2026-02-25Investigation of Psychedelic Effects in Psychoactive SubstancesClinicalTrials.gov · 2026-02-23Psychedelic Healing: Adjunct Therapy Harnessing Opened MalleabilityClinicalTrials.gov · 2026-02-13Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical TrialClinicalTrials.gov · 2026-02-12Psilocybin-Assisted Cognitive Behavioral Therapy for DepressionClinicalTrials.gov · 2026-02-12Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy VolunteersClinicalTrials.gov · 2026-02-05Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER: a Pilot StudyClinicalTrials.gov · 2026-02-05A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone TreatmentClinicalTrials.gov · 2026-01-23The STARLIGHT Protocol: State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing TraumaClinicalTrials.gov · 2026-01-22Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who StutterClinicalTrials.gov · 2025-12-22Investigating the Effects of a Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm Behaviour: an Experimental Medicine StudyClinicalTrials.gov · 2025-12-05Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication in Patients With Chronic Pain: an Open-label Feasibility StudyClinicalTrials.gov · 2025-12-04A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced CancerClinicalTrials.gov · 2025-12-04Psilocybin vs Ketamine for Alcohol Use DisorderClinicalTrials.gov · 2025-11-28Digital Intervention for Psychedelic Preparation (DIPP): A Randomised Controlled Feasibility Trial Comparing Meditation and Music-Based Programs in Healthy Volunteers.ClinicalTrials.gov · 2025-11-26Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive DisorderClinicalTrials.gov · 2025-11-26Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of LifeClinicalTrials.gov · 2025-11-25A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant DepressionClinicalTrials.gov · 2025-11-19Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.ClinicalTrials.gov · 2025-11-19Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use DisorderClinicalTrials.gov · 2025-11-17Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive DisorderClinicalTrials.gov · 2025-11-05A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic CancerClinicalTrials.gov · 2025-11-05A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?ClinicalTrials.gov · 2025-10-29Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older AdultsClinicalTrials.gov · 2025-10-21A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic CancerClinicalTrials.gov · 2025-10-14A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From MethamphetamineClinicalTrials.gov · 2025-10-07Retrospective Observational Study of Intensity Effects in Psychedelic-assisted TreatmentClinicalTrials.gov · 2025-10-02The Impact of Psilocybin on Pain in Fibromyalgia Patients: a Multicentre Trial.ClinicalTrials.gov · 2025-09-15The Safety, Feasibility, and Acceptability of Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain (P-PC)ClinicalTrials.gov · 2025-07-23Comparison of the Effects of PEX20 (Oral Psilocin), PEX30 (Sublingual Psilocin), and PEX10 (Oral Psilocybin) in Healthy AdultsClinicalTrials.gov · 2025-06-10Psilocybin With Intracranial Neural SensingClinicalTrials.gov · 2025-06-06Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)ClinicalTrials.gov · 2025-05-28Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive DisorderClinicalTrials.gov · 2025-05-14The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy TrainingClinicalTrials.gov · 2025-04-14Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAINClinicalTrials.gov · 2025-03-30Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in a Randomized, Placebo-controlled, Cross-over Trial in Healthy Participants (LPD-Study)ClinicalTrials.gov · 2025-03-27Molecular Imaging Study of Harmine/DMT: a Basic Research ApproachClinicalTrials.gov · 2025-03-19Beneficial effect of the combination psilocybin-semaglutide in a murine model of Steatotic Liver DiseaseDigestive and Liver Disease · 2025-02-01Direct effects of psilocybin on serotonin receptors regulate lipid accumulation in hepatic cells and adipocytesDigestive and Liver Disease · 2025-02-01Source Localized Auditory Erp Sensory and Preattentive Correlates of Psilocybin-Induced Ego-Dissolution Related EffectsDrug and Alcohol Dependence · 2025-02-01The Neurobiological Effect of 5-HT2AR ModulationClinicalTrials.gov · 2024-12-16A Registered Clinical Trial of PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy StudyClinicalTrials.gov · 2024-10-30The Effects of Psilocybin on Shared Experience in Film ProcessingClinicalTrials.gov · 2024-09-27An Open-Label Pilot Study Examining the Feasibility, Safety, and Effectiveness of Psilocybin Therapy for Depression in Bipolar II DisorderClinicalTrials.gov · 2024-09-25Psilocybin-assisted Psychotherapy in the Treatment of Patients Hospitalized for Treatment-resistant Depression: an Open-label Feasibility Study with an Experiential and Systemic FocusClinicalTrials.gov · 2024-09-19A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)ClinicalTrials.gov · 2024-08-15Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)Cognitive MechanismsClinicalTrials.gov · 2024-08-07Assessing the Feasibility of a Custom Psychedelic-assisted Group Program on Mental and Physical Health in First RespondersClinicalTrials.gov · 2024-06-24Licit use of illicit drugs for treating depression: the pill and the process.The Journal of clinical investigation · 2024-06-17A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use DisorderClinicalTrials.gov · 2024-06-10An Open-Label Investigation of the Effects of Sub-Perceptual Repeat Dosing of Psilocybin on the Behavioural and Cognitive Symptoms of Fragile X Syndrome in Adult PatientsClinicalTrials.gov · 2024-05-08Mechanisms Supporting Psilocybin-assisted Psychotherapy for Alcohol Use Disorder: A Randomized, Controlled Clinical TrialClinicalTrials.gov · 2024-05-07Non-psychedelic doses of psilocybin as a novel therapeutic approach for MASLDDigestive and Liver Disease · 2024-02-01Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of ActionClinicalTrials.gov · 2024-01-19Theorizing that Psychedelic Assisted Therapy May Play a Role in the Treatment of Trauma-Induced Personality Disorders.Journal of addiction psychiatry · 2024-01-01Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023-12-31A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-Assisted Psychotherapy in Treating Severe Depression Among Adults With Post-Traumatic Stress Disorder (PTSD).ClinicalTrials.gov · 2023-11-29An Open Label Pragmatic Feasibility Study on a Resilience Focused Community of Practice Program With Psilocybin-assisted Therapy (PaT) for End-of-Life Patients.ClinicalTrials.gov · 2023-07-25Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress DisorderClinicalTrials.gov · 2023-06-29Evaluation of the Acceptability, Safety, Feasibility, and Efficacy of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military VeteransClinicalTrials.gov · 2023-05-25Assessing potential of psilocybin for depressive disorders.Expert opinion on investigational drugs · 2023-01-01NW Trauma Therapies, Chronic Illness of Chronic Depression, PTSD, MS, HIV, and SARS-CoV-2, Long Haulers Syndrome. Treatment of Unregulaaible Trauma by the Treatment of Enhanced Micro Dosing the Levels of 0.15, Thru 0.33, With a Maintenance Dose of 1 Gram Per Month for Neural Pathway Increase of Non Synthesized Psilocybin, Using the Actual Plant to Regulate the Highjacked Nervous System.ClinicalTrials.gov · 2022-11-16Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD.Drug testing and analysis · 2022-08-01Tentative identification of in vitro metabolites of O-acetylpsilocin (psilacetin, 4-AcO-DMT) by UHPLC-Q-Orbitrap MS.Drug testing and analysis · 2022-07-01Psilocybin Versus Ketamine - Fast Acting Antidepressant Strategies in Treatment-resistant DepressionClinicalTrials.gov · 2022-05-20Further development of a liquid chromatography-high-resolution mass spectrometry/mass spectrometry-based strategy for analyzing eight biomarkers in human urine indicating toxic mushroom or Ricinus communis ingestions.Drug testing and analysis · 2021-09-01Stability of psilocybin and its four analogs in the biomass of the psychotropic mushroom Psilocybe cubensis.Drug testing and analysis · 2021-02-01Synthesis and characterization of high-purity N,N-dimethyltryptamine hemifumarate for human clinical trials.Drug testing and analysis · 2020-10-01The Psilocin (4-hydroxy-N,N-dimethyltryptamine) and Bufotenine (5-hydroxy-N,N-dimethyltryptamine) Case: Ensuring the Correct Isomer has Been IdentifiedJournal of Forensic Sciences · 2020-09-01A Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis.ClinicalTrials.gov · 2019-08-13Analysis of new psychoactive substances in oral fluids by means of microextraction by packed sorbent followed by ultra-high-performance liquid chromatography-tandem mass spectrometry.Drug testing and analysis · 2018-05-01Psilocybin and Depression - Assessing the Long-term Effects of a Single Administration of Psilocybin on the Psychiatric Symptoms and Brain Activity of Patients With Severe DepressionClinicalTrials.gov · 2017-12-21Designer Drugs 2.0.Clinical pharmacology and therapeutics · 2017-02-01Maddening Therapies: How Hallucinogens Morphed into Novel TreatmentsCurrent psychiatry · 2017-01-01Discovery of a new caerulescent Psilocybe mushroom in Germany: Psilocybe germanica sp.nov.Drug Testing and Analysis · 2015-03-31

Author directory

Robin Carhart-Harris176 publicationsDavid Nutt121 publicationsDavid Erritzøe84 publicationsFranz X. Vollenweider84 publicationsRoland R. Griffiths84 publicationsMatthew W. Johnson70 publicationsKatrin H. Preller64 publicationsFrederick S. Barrett61 publicationsGitte M. Knudsen57 publicationsLeor Roseman55 publicationsJames Rucker48 publicationsAlbert Garcia-Romeu46 publicationsTomáš Páleníček45 publicationsPatrick M. Fisher43 publicationsSandeep M. Nayak43 publicationsJoshua D. Rosenblat42 publicationsDea Siggaard Stenbæk41 publicationsKim P. C. Kuypers41 publicationsNatasha L. Mason38 publicationsPeter S. Hendricks38 publicationsAlan K. Davis36 publicationsDavid Bryce Yaden35 publicationsMatthias E. Liechti34 publicationsMuhammad Ishrat Husain34 publicationsChristopher Timmermann33 publicationsBrice Ozenne32 publicationsJohns Hopkins University31 publicationsGuy M. Goodwin30 publicationsHannes Kettner30 publicationsStephen Ross30 publicationsJohannes G. Ramaekers29 publicationsMichael P. Bogenschutz29 publicationsRoger S. McIntyre29 publicationsDirk Hoffmeister28 publicationsErich Seifritz27 publicationsRobert B. Kargbo27 publicationsRichard J. Zeifman26 publicationsBrian Anderson25 publicationsJavier González-Maeso25 publicationsMartin Korsbak Madsen25 publicationsAllan H. Young24 publicationsCharles D. Nichols24 publicationsDrummond E-Wen McCulloch24 publicationsGabrielle Agin-Liebes24 publicationsMartin Kuchař24 publicationsMorten L. Kringelbach24 publicationsNathan D. Sepeda24 publicationsXiaohui Wang24 publicationsNatalie Gukasyan23 publicationsPaul Liknaitzky23 publicationsFriederike Holze22 publicationsGustavo Deco22 publicationsScott Aaronson22 publicationsBrian S. Barnett21 publicationsBruna Giribaldi21 publicationsJacob S. Aday21 publicationsManoj Doss21 publicationsOlivia Carter21 publicationsOtto Simonsson21 publicationsRafael G. dos Santos21 publicationsAdam L. Halberstadt20 publicationsAlex Kwan20 publicationsJiřı́ Horáček20 publicationsMichael Kometer20 publicationsBenjamin Kelmendi19 publicationsBernard Lerer19 publicationsJaime E. C. Hallak19 publicationsMatthew B. Wall19 publicationsRoland A. Fischer19 publicationsRotem Petranker19 publicationsCharles L. Raison18 publicationsDavid E. Nichols18 publicationsEnzo Tagliazucchi18 publicationsFelix Müller18 publicationsFilip Tylš18 publicationsMendel Kaelen18 publicationsRobert A. Schoevers18 publicationsAlexander M. Sherwood17 publicationsAmanda Feilding17 publicationsChristopher S. Stauffer17 publicationsDavid J. Hellerstein17 publicationsFernando Rosas17 publicationsJeffrey Guss17 publicationsManish Agrawal17 publicationsMilan Scheidegger17 publicationsTomislav Majić17 publicationsWilliam A. Richards17 publicationsClaire J. Foldi16 publicationsJason B. Luoma16 publicationsKevin F. Boehnke16 publicationsLea J. Mertens16 publicationsMalievskaia E16 publicationsNadav Liam Modlin16 publicationsSophia Armand16 publicationsYale University16 publicationsAnna M. Becker15 publicationsCharles S. Grob15 publicationsEmmanuelle A. D. Schindler15 publicationsFelix Hasler15 publicationsGeyer MA15 publicationsJoshua S. Siegel15 publicationsKelly JR15 publicationsLindsey Marwood15 publicationsSuresh Muthukumaraswamy15 publicationsTzuri Lifschytz15 publicationsUniversity Hospital15 publicationsBoadie W. Dunlop14 publicationsBrandon Weiss14 publicationsChristopher Pittenger14 publicationsFederico Seragnoli14 publicationsGerhard Gründer14 publicationsGregor Hasler14 publicationsHenrik Jungaberle14 publicationsJanis Fricke14 publicationsJeng-Yu Tsai14 publicationsJennifer Jones14 publicationsJochen Gartz14 publicationsMeg J Spriggs14 publicationsMika Turkia14 publicationsNathalie M. Rieser14 publications